212 related articles for article (PubMed ID: 26927942)
21. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
[TBL] [Abstract][Full Text] [Related]
22. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
25. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Sultana A; Tudur Smith C; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
Br J Cancer; 2008 Jul; 99(1):6-13. PubMed ID: 18577990
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
28. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Inal A; Ciltas A; Yildiz R; Berk V; Kos FT; Dane F; Unek IT; Colak D; Ozdemir NY; Buyukberber S; Gumus M; Ozkan M; Isikdogan A
Asian Pac J Cancer Prev; 2012; 13(5):1841-4. PubMed ID: 22901133
[TBL] [Abstract][Full Text] [Related]
29. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G; Labianca R; Di Costanzo F; Gebbia V; Cartenì G; Massidda B; Dapretto E; Manzione L; Piazza E; Sannicolò M; Ciaparrone M; Cavanna L; Giuliani F; Maiello E; Testa A; Pederzoli P; Falconi M; Gallo C; Di Maio M; Perrone F; ; ;
J Clin Oncol; 2010 Apr; 28(10):1645-51. PubMed ID: 20194854
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Wang Y; Hu GF; Zhang QQ; Tang N; Guo J; Liu LY; Han X; Wang X; Wang ZH
Drug Des Devel Ther; 2016; 10():1961-72. PubMed ID: 27358556
[TBL] [Abstract][Full Text] [Related]
34. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Zhao WY; Chen DY
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):775-9. PubMed ID: 23291073
[TBL] [Abstract][Full Text] [Related]
35. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
36. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Eltawil KM; Renfrew PD; Molinari M
HPB (Oxford); 2012 Apr; 14(4):260-8. PubMed ID: 22404265
[TBL] [Abstract][Full Text] [Related]
38. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
